The global cell isolation market is growing at a significant rate i.e., 17.1% CAGR during 2021-2027 owing to the rising number of cancer patients, increasing prevalence of infectious diseases among the geriatric population, funding by the government for cell-based research, the increasing emphasis on personalized medicine and technological development. Moreover, the rising demand for biopharmaceuticals and the rising adoption of microfluidics technology in APAC countries will fuel the growth of the cell isolation market.

Th COVID19 pandemic has created an opportunity to study contagious diseases and develop treatments and diagnostic tools, propelling the demand for cell isolation tools in the research field. Several cell isolation technology companies, including Stemcell Technologies Inc., Akadeum Life Sciences, Miltenyi Biotec, and Nanocellect Biomedical, offer products for research on COVID 19 infections and support vaccine development. Nanocellect Biomedical has innovated the WOLF Benchtop Cell Sorter. It uses sterile, disposable cartridges that do not contaminate between samples and fits in a biosafety cabinet that ensures the safe handling of dangerous biological material.

Beckman Coulter, a clinical diagnostic company, has started the ARSCoV2 immunoglobulin M (IgM) assay. It has 99.9% specificity from 1,400 negative samples and 98.3% sensitivity at fifteen to thirty days post-symptom onset.

Request to get a free sample copy at https://www.vynzresearch.com/healthcare/cell-isolation-market/request-sample

Based on cell type, the human cell segment is expected to hold a significant share during 2021-2027 owing to the rising prominence of human cell therapy that injects live cells in a patient via cell isolation methods for treating various disorders. For instance, T-cells are injected into patients to treat cancer as they can fight against cancer cells during immunotherapy treatment. The increasing emphasis on human and cancer research and diverse applications of isolated human cells in biopharmaceuticals advancement, clinical trials, and research, favorable reimbursement policies regarding personalized medicine in emerging economies will propel the growth of the human cell isolation segment.

North America is anticipated to contribute to the largest share in the cell isolation market owing to well-established infrastructure for life science research, highly organized regulatory structure for companies to develop novel treatments, rise in spending on R&D by the private and public players will augment the growth in the region. Nevertheless, chronic and infectious diseases are becoming increasingly prominent. The COVID19 pandemic has increased the demand for cell isolation solutions for research and clinical applications

Thermo Fisher Scientific has acquired cell-sorting assets i.e., Bigfoot Spectral Cell Sorter from U.S.-based Propel Labs.

The prominent players in the cell isolation industry include Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Becton, Dickinson, and Company, Miltenyi Biotec, Terumo Corporation, General Electric Company, Stemcell Technologies Inc., Merck KGaA, and Pluriselect Life Science.

Source: VynZ Research